Toll Free: 1-888-928-9744

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016', provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- The report reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics and enlists all their major and minor projects
- The report assesses Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview 6 Therapeutics Development 7 Pipeline Products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview 7 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics under Development by Companies 8 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Products under Development by Companies 12 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development 13 CSL Limited 13 GeNeuro SA 14 Mitsubishi Tanabe Pharma Corporation 15 Octapharma AG 16 Pfizer Inc. 17 Shire Plc 18 Teijin Pharma Limited 19 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Combination Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 (hyaluronidase (human) (recombinant) + immune globulin (human)) - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 fingolimod hydrochloride - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 GL-2045 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 GNbAC-1 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 immune globulin (human) - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 immune globulin (human) - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 immune globulin (human) - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 immune globulin (human) - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects 52 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Product Development Milestones 53 Featured News & Press Releases 53 Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder 53 Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy 53 Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen 54 Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy 54 May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy 55 Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP 56 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by CSL Limited, H2 2016 13 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, H2 2016 14 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 15 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Octapharma AG, H2 2016 16 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc., H2 2016 17 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Shire Plc, H2 2016 18 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Teijin Pharma Limited, H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Assessment by Combination Products, H2 2016 21 Number of Products by Stage and Target, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, H2 2016 52



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify